CathWorks, a leader in digital health innovations, has received significant validation for its FFRangio System from the Society for Cardiovascular Angiography & Interventions (SCAI). On February 4, 2026, SCAI published an expert opinion emphasizing the growing importance of angiography-derived physiology (ADP), a method that eliminates the need for traditional wire-based assessments in coronary artery disease.
The SCAI document discusses how ADP leverages both advanced computational techniques and, in some cases, artificial intelligence (AI) to extract physiological insights from standard angiograms. This represents a significant advancement in the catheterization lab, as it enables more precise assessments without invasive procedures typically associated with coronary evaluations.
According to the expert opinion, the CathWorks FFRangio System is distinguished by its capability to derive multivessel fractional flow reserve (FFR) values across the entire coronary tree, including side branches. The system simulates pullbacks, which helps differentiate functional diseases and aids in planning percutaneous coronary interventions (PCI). This is a notable advantage over other systems, which may offer limited capabilities.
In clinical evaluations, CathWorks FFRangio has shown remarkable diagnostic accuracy, achieving a rate of 93% in a pooled analysis of five prospective studies, including the pivotal FAST-FFR study. Furthermore, it has demonstrated comparable rates of major adverse cardiac events (MACE) at one year when compared to invasive FFR methods, as seen in both real-world registries and the PROVISION RCT involving 400 patients.
The SCAI expert opinion highlights that the various ADP systems available differ significantly in terms of imaging requirements, integration into clinical workflows, and their computational methodologies. It stresses the importance of interpreting clinical data within the context of platform-specific validations. Notably, the CathWorks FFRangio System is the only FDA-approved ADP platform that consistently exhibits excellent diagnostic accuracy across multiple peer-reviewed studies.
In a statement, Ramin Mousavi, President and CEO of CathWorks, expressed enthusiasm for the growing body of clinical evidence supporting FFRangio. He anticipates that forthcoming guidelines in the United States and Europe will incorporate these peer-reviewed, evidence-based recommendations, thereby promoting broader adoption of physiological assessment technologies. This shift is expected to enhance procedural decision-making and ultimately improve patient outcomes.
As the landscape of cardiac diagnostics evolves, CathWorks FFRangio stands out as a transformative tool, offering rapid and reliable physiological assessments that could reshape the standard of care in coronary artery disease management. For further insights, the SCAI expert opinion can be accessed through their official publication platforms.
